Mesoblast Ltd

Healthcare AU MSB


Last update at 2024-02-22T05:10:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -82.10100M -91.58600M -99.63000M -87.35500M -98.75400M
Minority interest - - - - -
Net income -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Selling general administrative 25.37M 27.21M 30.87M 25.61M 21.62M
Selling and marketing expenses 27.73M 30.76M 32.72M 25.31M 15.36M
Gross profit -47.42100M -53.36100M -78.27500M -49.34100M 16.72M
Reconciled depreciation 4.11M 4.38M 4.26M 3.67M 2.14M
Ebit -69.13600M -80.95300M -111.86700M -79.07200M -83.30100M
Ebitda -65.02900M -76.57300M -107.60300M -75.40500M -81.16200M
Depreciation and amortization 4.11M 4.38M 4.26M 3.67M 2.14M
Non operating income net other - - - - -
Operating income -69.28900M -80.57400M -109.09600M -74.87200M -83.30100M
Other operating expenses 76.79M 90.78M 115.06M 107.56M 97.88M
Interest expense 19.44M 16.91M 10.71M 13.33M 11.33M
Tax provision -0.21200M -0.23900M -0.81900M -9.41500M -8.95500M
Interest income 18.78M 0.00300M 14.47M 14.47M 11.91M
Net interest income -19.29100M -17.28500M -10.71400M -13.33000M -10.98500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.21200M -0.23900M -0.81900M -9.41500M -8.95500M
Total revenue 7.50M 10.21M 7.46M 32.16M 16.72M
Total operating expenses 76.79M 90.78M 115.06M 107.56M 97.88M
Cost of revenue 54.92M 63.57M 85.73M 81.50M 15.36M
Total other income expense net 6.48M 6.27M 18.69M 1.38M -15.45300M
Discontinued operations - - - - -
Net income from continuing ops -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Net income applicable to common shares -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 669.41M 662.14M 744.72M 733.60M 652.12M
Intangible assets 442.73M 444.20M 446.09M 447.15M 448.67M
Earning assets - - - - -
Other current assets 0.40M 5.40M 6.76M 5.90M 8.29M
Total liab 167.58M 165.10M 163.32M 184.28M 171.06M
Total stockholder equity 501.84M 497.04M 581.40M 549.33M 481.05M
Deferred long term liab - - - - -
Other current liab 5.43M 2.19M 74.67M 65.17M 17.26M
Common stock 1249.12M 1165.31M 1163.15M 1051.45M 910.40M
Capital stock 1249.12M 1165.31M 1163.15M 1051.45M 910.40M
Retained earnings -820.80500M -738.91600M -647.56900M -548.75800M -469.99100M
Other liab 19.11M 15.02M 19.52M 30.79M 59.45M
Good will 134.45M 134.45M 134.45M 134.45M 134.45M
Other assets 2.33M 1.93M 1.72M 3.31M 3.32M
Cash 70.92M 60.03M 136.88M 129.33M 50.43M
Cash and equivalents -0.00200M 0.01M -0.04900M 0.01M 0.02M
Total current liabilities 41.98M 51.37M 94.27M 90.14M 44.33M
Current deferred revenue 6.40M 17.91M -55.96500M -35.97400M -
Net debt 45.58M 46.87M -31.38600M -30.01400M 30.86M
Short term debt 10.01M 8.20M 55.97M 35.97M 14.01M
Short long term debt 5.95M 5.02M 53.20M 32.45M 14.01M
Short long term debt total 116.50M 106.91M 105.50M 99.31M 81.29M
Other stockholder equity -428.31800M -426.39300M -515.58400M -502.69200M 48.35M
Property plant equipment 6.49M 9.96M 12.14M 10.27M 0.83M
Total current assets 81.66M 69.84M 148.23M 136.55M 62.52M
Long term investments 1.76M 1.76M 2.08M 1.87M 2.32M
Net tangible assets -75.34500M -81.60800M 0.85M -32.27500M -102.07400M
Short term investments - - - - -
Net receivables 7.00M 4.40M 4.84M 1.57M 4.06M
Long term debt 102.81M 91.62M 41.05M 57.02M 67.28M
Inventory - - -0.25200M -0.25200M -
Accounts payable 20.14M 23.08M 19.60M 24.97M 13.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 73.52M 70.65M 65.81M 46.63M 40.64M
Additional paid in capital - - - - -
Common stock total equity - - - 1051.45M 910.40M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.48M 1.68M 1.72M 3.31M 3.32M
Deferred long term asset charges - - - - -
Non current assets total 587.76M 592.30M 596.49M 597.05M 589.59M
Capital lease obligations 7.73M 10.27M 11.25M 9.84M -
Long term debt total 106.48M 98.70M 49.53M 63.34M 67.28M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.19400M -0.23200M -1.64700M -3.27300M -1.00000M
Change to liabilities -0.39800M 4.78M -5.06100M 14.01M -2.24300M
Total cashflows from investing activities -0.19400M -0.23200M -1.64700M -3.27300M -1.00000M
Net borrowings -2.65600M -6.32700M -2.93100M -1.62500M 43.57M
Total cash from financing activities 74.50M -9.87000M 114.47M 137.04M 71.61M
Change to operating activities 0.43M -0.04800M -1.61800M -1.60700M 17.71M
Net income -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Change in cash 10.87M -76.43400M 7.55M 78.90M 12.66M
Begin period cash flow 60.45M 136.88M 129.33M 50.43M 37.76M
End period cash flow 71.32M 60.45M 136.88M 129.33M 50.43M
Total cash from operating activities -63.26900M -65.78200M -106.68100M -56.36500M -57.79000M
Issuance of capital stock 88.64M 0.21M 106.27M 144.95M 30.26M
Depreciation 4.11M 4.38M 4.26M 3.67M 2.14M
Other cashflows from investing activities 0.07M -0.07500M 0.12M -1.17700M -0.72100M
Dividends paid 0.00000M 0.00000M - 0.00000M -
Change to inventory - - - - -
Change to account receivables -0.11800M 0.14M -1.73900M 0.89M 4.97M
Sale purchase of stock 88.64M 8.29M 119.24M 144.95M 30.26M
Other cashflows from financing activities -11.47700M 48.17M 11.13M -5.76500M 43.49M
Change to netincome 16.98M 16.32M -3.71600M 4.62M 9.43M
Capital expenditures 0.31M 0.23M 1.65M 2.25M 0.28M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.47200M 4.87M -8.41800M 13.29M 20.44M
Stock based compensation 3.65M 5.54M 12.51M 7.52M 4.37M
Other non cash items 13.54M 11.02M -15.40700M 6.51M 14.02M
Free cash flow -63.58300M -66.01400M -108.32800M -58.61100M -58.06900M


  • Previous Close 0.29
  • Market Cap248.87M
  • Volume929136
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-66.84300M
  • Revenue TTM7.50M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -47.42100M
  • Diluted EPS TTM-0.13


ASX : MSB announces annual results, emphasizing shareholder value with a final dividend declaration.
View all ASX announcements Click Here

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Mesoblast Ltd
0.0 0.0% 0.29 0.0 454.55 33.18 0.31 40.77 -5.2228
0.75 0.26% 285.02 36.63 31.35 9.71 5.25 11.02 35.26
Telix Pharmaceuticals Ltd
-0.03 0.27% 10.97 0.0 60.98 9.99 46.85 9.79 -135.9258
Neuren Pharmaceuticals Ltd
0.05 0.25% 20.18 45.86 38.76 33.42 32.44 198.10 53.50
Imugene Ltd
0.0 0.0% 0.11 0.0 0.0 69.06 4.29 0.0 -12.9293

Reports Covered

Stock Research & News


Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Ltd

55 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director 1957
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director 1951
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer NA
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer 1964
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec. 1968
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders NA
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering 1977
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management NA
Mr. Justin Horst B.S. Head of Manufacturing NA
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).